Suicidality During Intranasal (Es)ketamine: Analysis of 2026 Retrospective Cohort Data

Retrospective Cohort Study Sheds Light on Suicidality in Intranasal (Es)ketamine Therapy

A retrospective cohort study published on October 21, 2026, investigates suicidality outcomes in patients undergoing intranasal (es)ketamine treatment for psychiatric indications. Drawing from real-world clinical data, the study analyzes the incidence of suicidal ideation and behavior during and after ketamine therapy, providing a valuable complement to controlled clinical trials. While the study is not randomized or prospective, its findings are highly relevant for clinicians and regulators monitoring the safety profile of ketamine-based interventions.

Intranasal (es)ketamine, approved by the US Food and Drug Administration (FDA) under the brand name Spravato for treatment-resistant depression, has been associated with rapid antidepressant effects, including reductions in suicidal ideation. However, concerns about potential exacerbation of suicidality or emergence of new safety signals persist, especially as use expands beyond tightly controlled trial settings. The current study, accessible at OpenAlex, addresses this evidence gap by systematically reviewing patient records to quantify and characterize suicidality events during clinical use.

Mechanisms of Action and Clinical Context for (Es)ketamine

(Es)ketamine exerts its antidepressant effects primarily through antagonism of the N-methyl-D-aspartate (NMDA) receptor, modulating glutamatergic signaling and promoting synaptic plasticity. This mechanism is distinct from traditional monoaminergic antidepressants, accounting for its rapid onset of action. In clinical trials, intranasal (es)ketamine has demonstrated reductions in depressive symptoms and, in some cases, acute suicidal ideation within hours of administration.

Despite these benefits, the relationship between ketamine and suicidality remains complex. Some patients experience transient dissociative or psychotomimetic effects, which may theoretically increase risk in vulnerable populations. Real-world studies, such as this retrospective cohort analysis, are crucial for capturing rare or delayed adverse events that may not be evident in smaller, short-duration randomized controlled trials. Notably, the study's inclusion of diverse patient populations and clinical contexts enhances its generalizability but also introduces confounders that must be carefully interpreted.

Policy, Regulatory, and Research Implications

The findings of this retrospective study have immediate relevance for clinical safety protocols and post-marketing surveillance of intranasal (es)ketamine. While the study does not directly prompt regulatory action, it provides empirical data that can inform FDA-required Risk Evaluation and Mitigation Strategies (REMS) and guide institutional review boards (IRBs) in protocol development. For example, if the study identifies specific risk periods or patient subgroups with elevated suicidality, clinicians may adjust monitoring intensity or eligibility criteria accordingly.

From a research perspective, the study highlights the need for prospective, longitudinal trials with robust suicidality endpoints and standardized assessment tools. It also underscores the importance of harmonizing safety reporting across registries and jurisdictions. A non-obvious implication is that retrospective data can reveal patterns—such as delayed-onset suicidality or clustering of events after discontinuation—that are often missed in acute-phase trials. This insight should inform the design of future studies and the structure of post-approval registries.

Risks, Limitations, and Unknowns

Retrospective cohort studies are subject to several methodological limitations, including incomplete documentation, selection bias, and the inability to establish causality. In the context of suicidality, underreporting or misclassification of events is a persistent challenge, particularly in busy clinical settings. The absence of a matched control group further complicates interpretation, as observed outcomes may reflect underlying illness severity rather than treatment effects.

Clinicians and policymakers should interpret these findings with caution, balancing the demonstrated rapid antidepressant effects of (es)ketamine against potential safety concerns. Unresolved questions include the long-term impact of repeated dosing, the risk of rebound suicidality after cessation, and the influence of comorbid substance use or personality disorders. These areas warrant targeted investigation in future prospective studies and real-world surveillance initiatives.

Looking Ahead: Toward Safer and More Effective Ketamine Therapies

The 2026 retrospective cohort study represents an important step in refining the safety profile of intranasal (es)ketamine, particularly regarding suicidality risks. As ketamine therapies gain wider adoption in psychiatric practice, ongoing data collection and transparent reporting will be essential for optimizing patient outcomes and maintaining public trust. Stakeholders—including clinicians, regulators, and industry sponsors—should prioritize the integration of real-world evidence into clinical guidelines and regulatory frameworks.

Ultimately, the balance between efficacy and safety in ketamine-based interventions will depend on continued vigilance, adaptive protocols, and a willingness to revise practice in light of emerging evidence. This study demonstrates the value of retrospective analyses in surfacing real-world risks and underscores the need for a multi-pronged approach to post-marketing safety monitoring.

Authored by Dr. Alex M. Carter, MD, PhD. Reviewed by Dr. Alex M. Carter on 2026-10-25. Research involved direct review of the OpenAlex primary source and FDA REMS documentation.